China moves closer to the dream of Universal Health Coverage by improving the access to rare disease treatment by inclusion of rare disease medicines in the medicare reimbursement list.
The National Medical Product Administration prioritizes the rare disease drug review and speeds up the approval. In 2021, 7 rare-disease medicines have been included in the pharmaceutical reimbursement list under the national health insurance with an average price reduction of 65 percent.
To date, over 40 rare disease medicines have been included in the reimbursement list and more than 500 collaborative studies on rare diseases have been in progress in national key labs and translational medicine centers of China.
For more information, read the full news article originally published in China Daily.
Have anything to say about China’s health financing and social health protection? Please leave your comments below.
Photo by CarmenMurillo
